University of Connecticut

Medicinal Chemistry

School of Pharmacy


Structure-based design of ligands for treating infectious diseases
Development of new therapeutics effective in fighting infectious diseases remains critical in this age of multiple drug resistance, bioterrorism and the introduction of evolving infectious organisms. Research in the Anderson lab focuses on the design of new drugs for infectious diseases. Current projects include the design of antibacterial and antifungal compounds that will be effective against Staphylococcus aureus (MRSA), Klebsiella pneumoniae, Candida albicans and Candida glabrata infections. Work in the laboratory is multi-disciplinary and incorporates many of the processes of early-stage drug development: protein structure determination by various techniques, computational modeling of protein:inhibitor interactions, biochemical enzyme inhibition assays, cell growth inhibition and in vitro pharmacokinetic studies.